Einzeltreffer — DigiBib

Objective: This study aims to assess the clinical efficacy and safety of CHF-II in combination with RG for treating AKI on CKD (A on C), and to explore potential therapeutic mechanisms through lipidomics analysis.

Methods: 98 patients were enrolled and randomly assigned to the RG or RG + CHF groups. Both groups received RG therapy, with RG + CHF group additionally receiving CHF-II treatment over a duration of two weeks. Evaluation endpoints included changes in renal function, blood lipid profiles, urinary AKI biomarkers, and TCM symptoms before and after treatment. Serum samples were collected for lipid metabolite analysis.

Results: The total clinical effective rate in RG + CHF group was 73.5%, and that of RG group was 40.8%. TCM syndrome scores in RG + CHF group showed a more pronounced decrease ( p < 0.05). Scr, BUN, and UA levels decreased while eGFR levels increased in both groups ( p < 0.05), with a greater magnitude of change observed in the RG + CHF group. Urinary AKI biomarkers decreased more in RG + CHF group ( p < 0.05). No serious adverse events occurred during the trial. 58 different lipid metabolites and 48 lipid biomarkers were identified. According to the KEGG database, the possible metabolic pathways involved triglyceride metabolic pathway and fat digestion and absorption metabolic pathways.

Conclusion: CHF-II effectively alleviated kidney injury and improved TCM syndrome scores in patients with A on C. Lipid differential metabolites could serve as diagnostic indicators for AKI in patients with CKD. The possible metabolic pathways might be implicated in therapeutic action of CHF-II in the prevention and treatment of patients with A on C.

Titel:	Exploring therapeutic mechanisms of Chuan Huang Fang-II in the treatment of acute kidney injury on chronic kidney disease patients from the perspective of lipidomics.
Autor/in / Beteiligte Person:	Chen, L ; Wang, Q ; Li, T ; Li, L ; Wang, C ; Xu, B ; Gong, X
Link:	Full Text Finder (Volltext)
Zeitschrift:	Renal failure, Jg. 46 (2024-12-01), Heft 1, S. 2356021
Veröffentlichung:	London : Informa Healthcare ; <i>Original Publication</i>: New York, N.Y. : M. Dekker, c1987-, 2024
Medientyp:	academicJournal
ISSN:	1525-6049 (electronic)
DOI:	10.1080/0886022X.2024.2356021
Schlagwort:	Humans Male Female Middle Aged Aged Adult Lipids blood Glomerular Filtration Rate drug effects Treatment Outcome Medicine, Chinese Traditional methods Acute Kidney Injury etiology Acute Kidney Injury drug therapy Drugs, Chinese Herbal therapeutic use Lipidomics Renal Insufficiency, Chronic complications Renal Insufficiency, Chronic drug therapy Biomarkers blood Biomarkers urine
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Randomized Controlled Trial Language: English [Ren Fail] 2024 Dec; Vol. 46 (1), pp. 2356021. <i>Date of Electronic Publication: </i>2024 May 24. MeSH Terms: Acute Kidney Injury* / etiology ; Acute Kidney Injury* / drug therapy ; Drugs, Chinese Herbal* / therapeutic use ; Lipidomics* ; Renal Insufficiency, Chronic* / complications ; Renal Insufficiency, Chronic* / drug therapy ; Biomarkers* / blood ; Biomarkers* / urine ; Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Lipids / blood ; Glomerular Filtration Rate / drug effects ; Treatment Outcome ; Medicine, Chinese Traditional / methods References: EClinicalMedicine. 2024 Mar 14;70:102535. (PMID: 38516106) ; Am J Kidney Dis. 2021 Nov;78(5):719-727. (PMID: 34051308) ; JAMA Intern Med. 2024 Apr 1;184(4):414-423. (PMID: 38407862) ; Kidney Int. 2017 Nov;92(5):1071-1083. (PMID: 28890325) ; Inflammation. 2020 Apr;43(2):629-640. (PMID: 31828589) ; Crit Rev Clin Lab Sci. 2021 Aug;58(5):354-368. (PMID: 33556265) ; JAMA Netw Open. 2022 May 2;5(5):e2212709. (PMID: 35583867) ; Am J Kidney Dis. 2022 Apr;79(4):483-485. (PMID: 35181156) ; Am J Nephrol. 2021;52(9):693-701. (PMID: 34569479) ; Int J Mol Sci. 2021 Jan 15;22(2):. (PMID: 33467546) ; Nephrol Dial Transplant. 2017 Jan 1;32(1):24-31. (PMID: 27387474) ; Evid Based Complement Alternat Med. 2022 Mar 15;2022:1099642. (PMID: 35341156) ; Nat Rev Nephrol. 2024 Feb;20(2):137-146. (PMID: 37653237) ; Front Pharmacol. 2023 Apr 20;14:1101036. (PMID: 37153766) ; BMC Nephrol. 2020 Apr 25;21(1):149. (PMID: 32334566) ; QJM. 2023 Jul 04;:. (PMID: 37402613) ; Intensive Care Med. 2018 Mar;44(3):323-336. (PMID: 29541790) ; Phytomedicine. 2020 Oct;77:153266. (PMID: 32629383) ; Metabolites. 2021 Feb 23;11(2):. (PMID: 33672315) ; Nutrients. 2021 Sep 09;13(9):. (PMID: 34579015) ; N Engl J Med. 2023 Jan 12;388(2):179-180. (PMID: 36630627) ; Am J Physiol Renal Physiol. 2016 May 15;310(10):F1136-47. (PMID: 26911846) ; Semin Nephrol. 2020 Mar;40(2):232-242. (PMID: 32303285) ; Front Pharmacol. 2022 Oct 03;13:969107. (PMID: 36263137) ; Ann Plast Surg. 2017 Dec;79(6):623-630. (PMID: 28737560) ; BMC Nephrol. 2018 May 2;19(1):102. (PMID: 29720115) ; Crit Care. 2018 May 12;22(1):126. (PMID: 29751827) ; J Lipid Res. 2021;62:100024. (PMID: 33453220) ; Front Pharmacol. 2022 Jan 25;13:820071. (PMID: 35145414) ; J Clin Med. 2019 Aug 28;8(9):. (PMID: 31466281) ; Am J Kidney Dis. 2015 Dec;66(6):993-1005. (PMID: 26253993) ; Kidney Int. 2020 Aug;98(2):294-309. (PMID: 32709292) ; Nat Rev Nephrol. 2022 Jan;18(1):38-55. (PMID: 34616096) ; Lancet. 2019 Nov 23;394(10212):1949-1964. (PMID: 31777389) ; Nephron Clin Pract. 2014;127(1-4):180-4. (PMID: 25343846) ; J Biochem Mol Toxicol. 2021 Apr;35(4):e22696. (PMID: 33421258) ; Am J Med Sci. 2019 Jul;358(1):45-50. (PMID: 31079840) ; Redox Biol. 2022 Aug;54:102382. (PMID: 35767918) ; Front Pharmacol. 2018 Feb 08;9:53. (PMID: 29472858) Contributed Indexing: Keywords: Chuan Huang Fang-II; acute kidney injury; chronic kidney disease; lipidomics; therapeutic mechanisms Substance Nomenclature: 0 (Drugs, Chinese Herbal) ; 0 (Biomarkers) ; 0 (Lipids) Entry Date(s): Date Created: 20240524 Date Completed: 20240524 Latest Revision: 20240530 Update Code: 20240530 PubMed Central ID: PMC11132756

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Exploring therapeutic mechanisms of Chuan Huang Fang-II in the treatment of acute kidney injury on chronic kidney disease patients from the perspective of lipidomics.